Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oleclumab and Durvalumab in Advanced Solid Tumors
NCT02503774Phase 1Completed
- Sponsor
- MedImmune
- Start
- Jul 2015
- Primary completion
- Jan 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of oleclumab in solid tumor, colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC) and 1 more (3 arms), sponsored by MedImmune. Primary endpoints: Number of Participants With Dose Limiting Toxicities at 28 days, Number of Participants With Treatment Emergent Adverse Events at 200.1 weeks and 3 more. Started Jul 2015; status: completed.
02
Drugs
oleclumab
03
Conditions
solid tumorcolorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02503774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503774.